A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) GRADE 1-3A OR R/R MARGINAL ZONE LYMPHOMA (MZL)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Follicular/marginal Zone Lymphoma
-
Age: Between 18 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Histologically confirmed Grade 1, 2 or 3a follicular lymphoma (FL) or histologically confirmed nodal MZL, splenic MZL, or extranodal MZL of the mucosa-associated lymphoid tissue (MALT). 2) Must have been previously treated with at least 1 prior systemic anti-CD20 immunotherapy or chemo-immunotherapy.
You may not be eligible for this study if the following are true:
-
1) Women who are pregnant or breastfeeding. 2) Any histology other than follicular lymphoma (FL) and marginal zone lymphoma (MZL) or clinical evidence of transformed lymphoma by investigator assessment. 3) History of radiation therapy to = 25% of the bone marrow for other diseases.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
